Review
Pharmacology & Pharmacy
Ahmed O. Elzoghby, Cristina R. Ferrone, Soldano Ferrone, Mahmoud L. Nasr
Summary: Pancreatic cancer is a highly aggressive and resistant type of cancer. This review highlights the recent advances in engineering nanomedicines to enhance the immune response against pancreatic cancer. Nanomedicines are used to increase the immunogenicity of cancer cells, deactivate cancer-associated fibroblasts, enhance the antigen-presenting capacity of dendritic cells, reverse the immunosuppressive nature of the tumor microenvironment, and improve the infiltration of cytotoxic T lymphocytes for efficient antitumor immune responses.
DRUG DISCOVERY TODAY
(2023)
Article
Chemistry, Multidisciplinary
Na Yu, Xi Zhang, Haiping Zhong, Jingqing Mu, Xingwei Li, Tao Liu, Xiaoguang Shi, Xing-Jie Liang, Shutao Guo
Summary: In this study, we constructed two sub-20-nm nanomedicines to enhance chemotherapy for pancreatic ductal adenocarcinoma (PDAC). The nanomedicines exhibited excellent compatibility and improved pharmacokinetic profiles, leading to high tumor accumulation. Pretreatment with one of the nanomedicines restored stromal homeostasis and facilitated the distribution and penetration of the other nanomedicine, resulting in tumor regression.
Article
Polymer Science
Neha Parveen, Afsana Sheikh, Mohammed A. S. Abourehab, Ritu Karwasra, Surender Singh, Prashant Kesharwani
Summary: Pancreatic cancer is the fourth leading cause of death worldwide, with low survival rates. The difficulties in early detection and the unique characteristics of pancreatic cancer contribute to ineffective therapies and widespread metastasis. Novel approaches, such as combining nanotechnology with cancer targeting, have shown potential in improving treatment efficacy and reducing cytotoxic effects.
EUROPEAN POLYMER JOURNAL
(2023)
Article
Chemistry, Multidisciplinary
Qi-Song Tong, Wei-Min Miao, Hua Huang, Jia-Qi Luo, Rong Liu, Yong-Cong Huang, Dong-Kun Zhao, Song Shen, Jin-Zhi Du, Jun Wang
Summary: A newly developed tumor-penetrating nanoparticle can modulate the deep microenvironment of PDAC, facilitating the effectiveness of chemoimmunotherapy.
Review
Oncology
Raul Ortiz, Francisco Quinonero, Beatriz Garcia-Pinel, Marco Fuel, Cristina Mesas, Laura Cabeza, Consolacion Melguizo, Jose Prados
Summary: Drug resistance is a major cause of cancer treatment failure, but nanotechnology has been identified as a potential alternative to overcome this issue, particularly in the treatment of colon and pancreatic cancers. Various nanotechnology-based therapies have shown efficacy in preclinical phases, offering new strategies to address drug resistance mechanisms in cancer cells.
Article
Nanoscience & Nanotechnology
Tanmoy Saha, Jayanta Mondal, Sachin Khiste, Hrvoje Lusic, Zhang-Wei Hu, Ruparoshni Jayabalan, Kevin J. Hodgetts, HaeLin Jang, Shiladitya Sengupta, Somin Eunice Lee, Younggeun Park, Luke P. Lee, Aaron Goldman
Summary: This research presents two innovative delivery strategies combining nanotechnology with cancer medicine to target different drug resistance mechanisms, bypassing resistance barriers through engineering strategies, and inducing cell killing through multimodal mechanisms including nanophotonic mechanisms.
Article
Nanoscience & Nanotechnology
Thanpisit Lomphithak, Apiwit Sae-Fung, Simone Sprio, Anna Tampieri, Siriporn Jitkaew, Bengt Fadeel
Summary: In this study, iron-doped hydroxyapatite (FeHA) was evaluated as a potential nanomedicine approach for treating PDAC. The results showed that FeHA, in combination with a sublethal dose of the GPX4 inhibitor RSL3, could trigger ferroptosis in KRAS mutant PANC-1 cells while sparing normal human cells. The induction of ferroptosis by FeHA plus RSL3 was found to be dependent on the metalloreductase STEAP3 in PDAC cells.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2024)
Review
Medicine, Research & Experimental
Maria Urbanova, Marina Cihova, Verona Buocikova, Jan Slopovsky, Peter Dubovan, Daniel Pindak, Miroslav Tomas, Laura Garcia-Bermejo, Mercedes Rodriguez-Garrote, Julie Earl, Yvonne Kohl, Agapi Kataki, Maria Dusinska, Bruno Sainz, Bozena Smolkova, Alena Gabelova
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer due to its desmoplastic stroma and immunosuppressive tumor microenvironment (TME). Remodeling the TME and targeting epigenetic pathways have become key therapeutic strategies. Nanotechnology offers new opportunities for enhancing drug efficacy through nano-based drug delivery systems (NDDSs), which provide advantages such as improved drug pharmacokinetics and enhanced tumor penetration.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Chemistry, Multidisciplinary
Girgis Obaid, Shazia Bano, Hanna Thomsen, Susan Callaghan, Nimit Shah, Joseph W. R. Swain, Wendong Jin, Xiadong Ding, Colin G. Cameron, Sherri A. McFarland, Juwell Wu, Mark Vangel, Svetla Stoilova-McPhie, Jie Zhao, Mari Mino-Kenudson, Charles Lin, Tayyaba Hasan
Summary: Desmoplasia, a characteristic of pancreatic ductal adenocarcinoma (PDAC), poses barriers to treatment and affects patient outcomes. This study demonstrates a novel targeted liposomal therapy that combines photodynamic and chemotherapeutic effects while also remediating desmoplasia. The results show significant inhibition of tumor growth and improved survival, highlighting the potential of this therapy in extending the lives of PDAC patients.
Review
Biology
Jorge A. Roacho-Perez, Elsa N. Garza-Trevino, Paulina Delgado-Gonzalez, Zuca G-Buentello, Juan Luis Delgado-Gallegos, Christian Chapa-Gonzalez, Margarita Sanchez-Dominguez, Celia N. Sanchez-Dominguez, Jose Francisco Islas
Summary: Pancreatic cancer is the most common lethal tumor in America, with limited treatment options and several side effects. Utilizing targeted nanoparticles as an alternative treatment for pancreatic cancer aims to reduce side effects and improve treatment outcomes by identifying and attacking cancer cells specifically.
Review
Pharmacology & Pharmacy
Tingting Hu, Hanlin Gong, Jiayue Xu, Yuan Huang, Fengbo Wu, Zhiyao He
Summary: This paper reviews the mechanisms of cancer drug resistance to chemotherapy, targeted therapy, and immunotherapy, and discusses the latest developments in nanomedicines for overcoming cancer drug resistance.
Article
Pharmacology & Pharmacy
Qiuhong Li, Kexin Chen, Tianyi Zhang, Donghui Jiang, Ligang Chen, Jun Jiang, Chunxiang Zhang, Shengbiao Li
Summary: Sorafenib is a key first-line treatment for liver cancer with a well-known safety profile. Although novel first-line drugs may have better efficacy, they also have limitations such as worse safety and cost-effectiveness. In addition to inducing apoptosis, Sorafenib can trigger ferroptosis, which has recently been recognized as immunogenic cell death, providing new possibilities for cancer treatment. Resistance to Sorafenib-induced ferroptosis remains a major challenge.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Catherine Passirani, Anne Vessieres, Giuseppe La Regina, Wolfgang Link, Romano Silvestri
Summary: Identifying and validating proteins involved in resistance mechanisms is crucial for innovative therapeutic strategies to improve the clinical outcome of cancer patients. Rational treatment strategies targeting transcription factors, pseudokinases, nuclear export receptors, and immunogenic cell death show promise in overcoming therapy resistance. The success in inhibiting specific proteins and pathways implicated in drug resistance illustrates the potential of targeted therapies and immunotherapies to improve clinical outcomes.
DRUG RESISTANCE UPDATES
(2022)
Article
Chemistry, Multidisciplinary
Yu Zhang, Sheng Ma, Xinming Liu, Yudi Xu, Jiayu Zhao, Xinghui Si, Hongxiang Li, Zichao Huang, Zhenxin Wang, Zhaohui Tang, Wantong Song, Xuesi Chen
Summary: A programmable immune activation nanomedicine (PIAN) is reported in this study, which sequentially finishes multiple steps after intravenous injection and elicits robust antitumor immunity in situ. This innovative approach provides a new framework for designing programmable nanomedicine as an in situ cancer vaccine for cancer immunotherapy.
ADVANCED MATERIALS
(2021)
Review
Biochemistry & Molecular Biology
Suhail Ahmad Mir, Laraibah Hamid, Ghulam Nabi Bader, Ambreen Shoaib, Mohamed Rahamathulla, Mohammad Y. Alshahrani, Prawez Alam, Faiyaz Shakeel
Summary: Cancer is a major cause of death worldwide, with millions of new cases and deaths reported each year. Chemotherapy, radiotherapy, and surgery are the main approaches to treating cancer, but they have limitations. Lack of target selectivity and drug resistance are major obstacles in cancer treatment. Nanotechnology-based drug therapies have shown great promise in overcoming resistance, with several nano-based drugs being explored at the clinical level.